Disease & disorder

cutaneous neuroendocrine carcinoma

MONDO:0019210

Cutaneous neuroendocrine carcinoma is a primary cutaneous cancer arising from a subset of skin neuroendocrine cells (Merkel cells, giving the name Merkel cell carcinoma (MCC)).

Clinical trials40
Recruiting8
Drug concepts studied18
Synonyms16

Research intelligence

Directly mapped studies only · unique clinical trials

Current registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.

Medications under investigation

Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.

Loading mapped interventions…

MONDO disease family

Loading verified ontology relationships…

Recruiting studies by city

Loading research-site locations…

Trial status

Loading…

Trial phase

Loading…

Study start year

Loading…

Investigated drug interventions

Loading…
Background context

Merkel-cell carcinoma

Merkel cell carcinoma (MCC) is an aggressive skin cancer occurring in about three thousand persons per year in the United States. It is also known as cutaneous APUDoma, primary neuroendocrine carcinoma of the skin, primary small-cell carcinoma of the skin, and trabecular carcinoma of the skin. Factors involved in the development of MCC include the Merkel cell polyomavirus (MCPyV or MCV), a weakened immune system, or exposure to ultraviolet radiation. Merkel cell carcinoma usually arises on the head, neck, and extremities, as well as in the perianal region and on the eyelid. It ‘most often presents in an older white population with a male predominance'; 'median age of presentation falls within the late seventh decade, despite a broad age range (fourth to tenth decades).’ MCC is less common in children.

Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

40 shown
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasNCT07285044 · 2025-12-18
RECRUITING
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid TumorsNCT07006727 · 2025-10-16
RECRUITING
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing TumorsNCT06814496 · 2025-09-08
RECRUITING
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsNCT07115043 · 2025-07-29
RECRUITING
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNCT06047379 · 2023-11-01
RECRUITING
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid TumorsNCT05076760 · 2022-04-21
RECRUITING
A Beta-only IL-2 ImmunoTherapY StudyNCT05086692 · 2021-08-27
RECRUITING
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC VirusNCT02479698 · 2015-07-23
RECRUITING
Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )NCT06939036 · 2025-07-01
TERMINATED
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsNCT05864144 · 2023-05-31
COMPLETED
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid TumorsNCT04616248 · 2023-01-09
ACTIVE_NOT_RECRUITING
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid TumorsNCT05120271 · 2022-10-26
ACTIVE_NOT_RECRUITING
Immunological Variables Associated to ICI Toxicity in Cancer PatientsNCT05429866 · 2022-09-01
UNKNOWN
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IONCT05078047 · 2022-03-08
ACTIVE_NOT_RECRUITING
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic CancerNCT04916002 · 2021-11-30
TERMINATED
Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung CancerNCT04590781 · 2021-05-10
TERMINATED
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid TumorsNCT04272034 · 2021-03-26
TERMINATED
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid TumorsNCT04725331 · 2021-02-25
TERMINATED
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell TherapyNCT04596033 · 2020-11-11
TERMINATED
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic CancersNCT04260802 · 2020-09-24
TERMINATED
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid TumorsNCT04242199 · 2020-09-04
COMPLETED
Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.NCT04276597 · 2020-03-04
WITHDRAWN
LITT and Pembrolizumab in Recurrent Brain MetastasisNCT04187872 · 2020-01-10
TERMINATED
Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid TumorsNCT04116320 · 2019-11-21
TERMINATED
A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell CarcinomaNCT04047251 · 2019-11-14
ACTIVE_NOT_RECRUITING
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid TumorsNCT04234113 · 2019-06-13
TERMINATED
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular ImmunotherapyNCT04106167 · 2019-06-11
TERMINATED
Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)NCT03783078 · 2019-02-25
COMPLETED
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsNCT03841110 · 2019-02-15
COMPLETED
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsNCT03228667 · 2018-12-11
ACTIVE_NOT_RECRUITING
A Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesNCT03652077 · 2018-09-24
COMPLETED
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced MalignanciesNCT03629756 · 2018-07-24
COMPLETED
DOTATOC PET/CT for Imaging NET PatientsNCT03583528 · 2018-07-11
ACTIVE_NOT_RECRUITING
A Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesNCT03538028 · 2018-06-18
COMPLETED
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor MalignanciesNCT03435640 · 2018-03-15
TERMINATED
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced CancersNCT03212404 · 2017-09-20
ACTIVE_NOT_RECRUITING
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersNCT02643303 · 2016-12-28
COMPLETED
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis FungoidesNCT02890368 · 2016-09-01
TERMINATED
BB-10901 in Treating Patients With Relapsed or Refractory Solid TumorsNCT00346385 · 2002-03-01
COMPLETED
Indium In 111 Pentetreotide in Treating Patients With Refractory CancerNCT00002947 · 1996-10-01
TERMINATED

Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.